Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis. We show 25 historical shares outstanding datapoints in our SRRA shares outstanding history coverage, used to compute SRRA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SRRA market cap history over the course of time is important for investors
interested in comparing SRRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SRRA versus a peer is one thing; comparing
SRRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SRRA can fluctuate over the course of history.
With this page we aim to empower investors researching SRRA by allowing them to research the SRRA market cap history. |
Free SRRA Email Alerts:
Video: The Importance of Market Cap
